Illumina Faces Proxy Battle Over Grail Acquisition
Carl Icahn has decided to take his beef with Illumina’s board of directors over the acquisition directly to company shareholders.
Carl Icahn has decided to take his beef with Illumina’s board of directors over the acquisition directly to company shareholders.
The deal closed Feb.22, but the FTC has expressed concerns about the acquisition and Amazon’s business practices in general.
Economic volatility and uncertainty is also making a significant impact on merger and acquisition activity in the diagnostics space.
Merger and acquisition deal volume and value were down last year, but deal impact was not.
M&A activity in the clinical diagnostics space was significantly down in 2022 in terms of both deal volume and deal value.